Clinical Trial

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the modern approach to GVHD prevention, GVHD rates have reduced markedly.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-11.
Trial Details
NCT Number NCT07302776
Lead Sponsor Stanford University
Collaborators: Eurofins Viracor Biopharma
Conditions GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Enrollment 50 participants
Start Date 2026-06
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-17